Zai Lab (ZLAB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 Jun, 2026Opening remarks and agenda
Meeting opened by the Chairperson, welcoming shareholders both in person and virtually, ensuring equal participation rights.
Inspector of Elections and Chief Legal Officer introduced to oversee proceedings and formalities.
Notice of meeting and proxy statement confirmed as duly distributed to all shareholders of record.
Q&A with stakeholders
Shareholders could submit questions in advance or during the meeting via the web portal, with responses provided as time allowed.
No written questions were received in advance, and no further questions were raised during the meeting.
Overview of voting outcomes
Quorum confirmed with more than half of all issued and outstanding shares represented.
Fourteen proposals were presented, including director reelections, auditor appointments, executive compensation, and share issuance/repurchase mandates.
All fourteen proposals were carried as ordinary resolutions following a poll vote.
Latest events from Zai Lab
- ZL-1310 demonstrates strong efficacy in small cell lung cancer, with pivotal trials and new assets advancing.ZLAB
Citi's 2025 Virtual Oncology Leadership Summit9 Jul 2026 - ZL1310 demonstrates strong efficacy and safety in small cell lung cancer, advancing to phase III trials.ZLAB
American Society of Clinical Oncology Annual Meeting 20259 Jul 2026 - Profitable China operations and rapid global pipeline progress drive growth and innovation.ZLAB
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q3 2024 revenue up 47% to $101.8M, net loss narrowed to $41.7M, with strong product growth.ZLAB
Q3 20248 Jul 2026 - Strong pipeline progress and commercialization plans position the company for major growth in China.ZLAB
Morgan Stanley 23rd Annual Global Healthcare Conference8 Jul 2026 - Q1 2026 revenue fell 6% YoY to $99.6M; pipeline and launches support future growth.ZLAB
Q1 20267 May 2026 - Key votes include director re-elections, auditor approval, and share issuance/repurchase mandates.ZLAB
Proxy filing28 Apr 2026 - Proxy covers director elections, auditor appointments, compensation, share mandates, and ESG strategy.ZLAB
Proxy filing28 Apr 2026 - Strong intracranial and systemic efficacy with favorable safety in SCLC and neuroendocrine tumors.ZLAB
Study update21 Apr 2026